Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Clinical research sponsor
Clinical trials
60 shownA Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate CancerNCT07711184 · lead sponsor · 2026-07-30
RECRUITINGA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast CancerNCT07497386 · lead sponsor · 2026-04-28
RECRUITINGA Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate CancerNCT07407283 · lead sponsor · 2026-04-08
RECRUITINGA Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 InjectionNCT07489482 · lead sponsor · 2026-04-02
RECRUITINGA Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07311694 · lead sponsor · 2026-02-02
RECRUITINGA Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerNCT07230106 · lead sponsor · 2025-12-08
RECRUITINGA Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerNCT07241416 · lead sponsor · 2025-12-05
RECRUITINGA Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung CancerNCT07232849 · lead sponsor · 2025-12-04
RECRUITINGA Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerNCT07241767 · lead sponsor · 2025-11-12
RECRUITINGPhase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer SubjectsNCT07175220 · lead sponsor · 2025-10-09
RECRUITINGA Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung CancerNCT07003321 · lead sponsor · 2025-09-12
RECRUITINGA Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 DiabetesNCT07032688 · lead sponsor · 2025-08-11
RECRUITINGA Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast CancerNCT06974929 · lead sponsor · 2025-05-22
RECRUITINGStudy of RSS0343 Tablets in Patients With Non-cystic Fibrosis BronchiectasisNCT06775340 · lead sponsor · 2025-01-22
RECRUITINGA Study of SHR-4394 Injection in Subjects With Prostate CancerNCT06783829 · lead sponsor · 2025-01-22
RECRUITINGA Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and PrednisoneNCT06689163 · lead sponsor · 2024-12-11
RECRUITINGA Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerNCT06568094 · lead sponsor · 2024-09-25
RECRUITINGA Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer PatientsNCT06555068 · lead sponsor · 2024-08-12
RECRUITINGA Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 MutationsNCT06430437 · lead sponsor · 2024-07-29
RECRUITINGStudy of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT05942001 · lead sponsor · 2023-08-03
RECRUITINGA Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerNCT05482568 · lead sponsor · 2022-09-15
RECRUITINGA Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLCNCT04316364 · lead sponsor · 2020-07-14
RECRUITINGA Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy ParticipantsNCT07610148 · lead sponsor · 2026-06-08
ACTIVE_NOT_RECRUITINGA Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic AgentsNCT07472725 · lead sponsor · 2026-04-11
ACTIVE_NOT_RECRUITINGA Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast CancerNCT07196774 · lead sponsor · 2025-10-23
ACTIVE_NOT_RECRUITINGA Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic DrugsNCT07018453 · lead sponsor · 2025-07-16
ACTIVE_NOT_RECRUITINGPhase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer PatientsNCT07056439 · lead sponsor · 2025-07-01
NOT_YET_RECRUITINGA Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy SubjectsNCT07014488 · lead sponsor · 2025-06-20
COMPLETEDInvestigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast CancerNCT06710990 · lead sponsor · 2025-02-17
COMPLETEDEfficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes SubjectsNCT06688123 · lead sponsor · 2025-01-08
COMPLETEDThe Experiment of Noiiglutide Injection in Type 2 Diabetes PatientsNCT06649773 · lead sponsor · 2024-11-06
COMPLETEDA Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor FluctuationsNCT06596876 · lead sponsor · 2024-11-06
COMPLETEDA Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 DiabetesNCT06871761 · lead sponsor · 2024-05-08
COMPLETEDComparison of HR011408 and NovoRapid® in Subjects With DiabeticsNCT06375031 · lead sponsor · 2024-05-01
UNKNOWNA Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 DiabetesNCT06881264 · lead sponsor · 2024-04-30
COMPLETEDA Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT06035393 · lead sponsor · 2024-01-15
TERMINATEDAssessment of Gastric Emptying by SHR20004 in Healthy SubjectsNCT06137469 · lead sponsor · 2023-12-26
COMPLETEDA Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant TherapyNCT06126640 · lead sponsor · 2023-11-20
ACTIVE_NOT_RECRUITINGA Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different SitesNCT06086912 · lead sponsor · 2023-11-07
COMPLETEDA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerNCT06057610 · lead sponsor · 2023-11-01
ACTIVE_NOT_RECRUITINGDalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)NCT06099990 · lead sponsor · 2023-10-01
NOT_YET_RECRUITINGPhase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate CancerNCT06062355 · lead sponsor · 2023-10-01
UNKNOWNPhase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate CancerNCT06006104 · lead sponsor · 2023-09-30
UNKNOWNA Trial of SP2086 With Hepatic InsufficiencyNCT06035406 · lead sponsor · 2023-09-01
UNKNOWNSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical TrialNCT05814354 · lead sponsor · 2023-06-30
ACTIVE_NOT_RECRUITINGA Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 DiabetesNCT05996380 · lead sponsor · 2023-06-09
UNKNOWNTo Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy SubjectsNCT05887895 · lead sponsor · 2023-05-23
COMPLETEDA Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and TabletsNCT05868057 · lead sponsor · 2023-05-23
COMPLETEDPharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor FluctuationsNCT06614153 · lead sponsor · 2023-05-16
COMPLETEDA SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer SubjectsNCT05607693 · lead sponsor · 2023-04-26
UNKNOWNA Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.NCT05792410 · lead sponsor · 2023-04-01
UNKNOWNTo Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic DrugsNCT05699408 · lead sponsor · 2023-03-31
COMPLETEDTo Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.NCT05702073 · lead sponsor · 2023-03-31
COMPLETEDThe Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy SubjectNCT05737576 · lead sponsor · 2023-03-20
COMPLETEDBioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy SubjectsNCT05719961 · lead sponsor · 2023-01-05
UNKNOWNA Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil PhenotypeNCT05522439 · lead sponsor · 2022-12-22
COMPLETEDStudy of SHR6390 in Renal Insufficiency and Healthy SubjectsNCT05515289 · lead sponsor · 2022-12-18
UNKNOWNA Trial of HR17031 Injection With Renal InsufficiencyNCT05292495 · lead sponsor · 2022-10-12
COMPLETEDA Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerNCT05042375 · lead sponsor · 2022-09-08
UNKNOWNA Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneNCT05424835 · lead sponsor · 2022-08-04
ACTIVE_NOT_RECRUITINGSponsor roles
lead sponsor188
collaborator72
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.